Sanofi Total Assets 2011-2026 | SNY

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets Sanofi

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
133 B	126 B	127 B	120 B	114 B	113 B	111 B	99.8 B	105 B	102 B	97.4 B	96.1 B	100 B	100 B

All numbers in EUR currency

Indicator range from annual reports

Maximum	Minimum	Average
133 B	96.1 B	110 B

Quarterly Total Assets Sanofi

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	120 B	-	112 B	-	114 B	-	116 B	-	113 B	-	-	-	111 B	-	-	-	99.8 B	-	-	-	105 B	-	-	-	102 B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in EUR currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
120 B	99.8 B	110 B

Total Assets of other stocks in the Biotechnology industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	2.03 B	-	2.43 %	$ 254 M	Germany
ARCA biopharma ABIO	396 M	-	1052.0 %	$ 415 M	USA
Acasti Pharma ACST	72 M	-	4.01 %	$ 150 M	Canada
Adverum Biotechnologies ADVM	180 M	-	-	$ 86.2 M	USA
AgeX Therapeutics AGE	12 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	778 M	-	-	$ 1.01 B	USA
AIkido Pharma AIKI	47.1 M	-	1.93 %	$ 17.4 M	USA
I-Mab IMAB	6.33 B	-	-	$ 866 M	China
Aptorum Group Limited APM	16.1 M	$ 0.81	0.15 %	$ 4.42 M	China
argenx SE ARGX	6.2 B	$ 836.39	-0.46 %	$ 25 B	Niderland
Alexion Pharmaceuticals, Inc. ALXN	18.1 B	-	-	$ 40.3 B	USA
Akero Therapeutics AKRO	826 M	-	-	$ 3.67 B	USA
Ascendis Pharma A/S ASND	1.3 B	$ 234.52	-0.2 %	$ 5 B	Danmark
Biophytis SA BPTS	12 M	-	-13.47 %	$ 169 M	France
Albireo Pharma ALBO	302 M	-	-0.23 %	$ 916 M	USA
Alterity Therapeutics Limited ATHE	41.4 M	$ 3.44	3.42 %	$ 8.28 B	Australia
Allena Pharmaceuticals ALNA	34.8 M	-	3.16 %	$ 1.9 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	15.2 M	-	-1.52 %	$ 24.7 M	USA
AlloVir ALVR	119 M	-	4.14 %	$ 49.1 M	USA
Midatech Pharma plc MTP	14.8 M	-	-18.52 %	$ 27.3 M	Britain
Akouos AKUS	279 M	-	0.23 %	$ 488 M	USA
BioVie BIVI	21.6 M	$ 1.24	-0.8 %	$ 1.83 M	USA
Ampio Pharmaceuticals AMPE	5.74 M	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	107 M	-	-	$ 10.1 M	USA
BioMarin Pharmaceutical BMRN	6.99 B	$ 61.58	-1.66 %	$ 11.7 B	USA
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Atea Pharmaceuticals AVIR	465 M	$ 4.56	-1.94 %	$ 384 M	USA
Acer Therapeutics ACER	11.6 M	-	2.71 %	$ 14 M	USA
Aravive ARAV	62.2 M	-	-13.39 %	$ 1.45 M	USA
Институт стволовых клеток человека ISKJ	1.51 B	-	-	-	Russia
Applied Genetic Technologies Corporation AGTC	66.7 M	-	-	$ 26.5 M	USA
Avenue Therapeutics ATXI	2.67 M	-	-52.27 %	$ 4.45 M	USA
Capricor Therapeutics CAPR	58.7 M	$ 28.24	1.18 %	$ 756 M	USA
Axsome Therapeutics AXSM	690 M	$ 165.14	-2.83 %	$ 8.22 B	USA
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
CASI Pharmaceuticals CASI	138 M	$ 0.31	-61.59 %	$ 42.2 M	USA
Atreca BCEL	155 M	-	-11.76 %	$ 5.79 M	USA
Alpine Immune Sciences ALPN	287 M	-	-	$ 2.17 B	USA
BioDelivery Sciences International BDSI	325 M	-	-4.8 %	$ 255 M	USA
Catalyst Biosciences CBIO	117 M	$ 12.21	-3.48 %	$ 804 M	USA
Aeterna Zentaris AEZS	35.1 M	-	5.93 %	$ 314 M	Canada
BeiGene, Ltd. BGNE	5.92 B	-	0.49 %	$ 251 B	Cayman-islands
Biogen BIIB	29.4 B	$ 191.78	-1.72 %	$ 28.1 B	USA
Bellicum Pharmaceuticals BLCM	23.8 M	-	-9.72 %	$ 5.89 M	USA
Baudax Bio BXRX	10 M	-	0.59 %	$ 63 K	USA
Aptose Biosciences APTO	10.1 M	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	66.7 M	-	-39.0 %	$ 4.57 M	USA
Aridis Pharmaceuticals ARDS	14.7 M	-	17.91 %	$ 11.1 M	USA
BioNTech SE BNTX	22.5 B	$ 110.5	-0.35 %	$ 27.2 B	Germany
Amneal Pharmaceuticals AMRX	3.5 B	$ 14.64	-0.17 %	$ 4.52 B	USA